((自动化翻译由路透提供，请见免责声明 )) (第 2-4 段增加了交易细节)
路透9月18日 - 医疗保健公司Organon 周三表示，已同意以不超过12亿美元的价格收购Roivant 旗下皮肤疗法开发商Dermavant。
Organon公司将支付1.75亿美元的预付款，以及7500万美元的里程碑付款，在达到某些商业里程碑时最高支付9.5亿美元。
Dermavant 的 VTAMA 银屑病膏于 2022 年 5 月获得美国食品和药物管理局批准。银屑病是一种常见的慢性炎症性皮肤病。
公司预计将在今年第四季度完成交易。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.